The U.S. Food and Drug Administration unveiled the first cohort of companies selected for its Commissioner’s National Priority Voucher (CNPV) pilot, a program designed to cut review times for designated "national priority" products to as little as one to two months. The agency named nine recipients, spanning small biotechs and large pharmas, and said qualifying products must address unmet national needs or boost domestic manufacturing. Regulators intend the pilot to accelerate approvals for candidates ranging from rare-disease therapies to oncology assets; winners could receive a regulatory decision in weeks rather than the standard months. Companies named include Disc Medicine and firms planning pivotal submissions, which could translate into approvals before year-end if reviews go smoothly. The FDA framed the pilot as a test of priority-review logistics; industry watchers flagged potential downstream effects on reviewer workload and portfolio planning. The CNPV rollout also prompted market moves: investors reacted to company-specific prospects tied to voucher-driven timelines. Observers flagged questions about selection transparency and long-term policy design, since the pilot expands the agency’s discretionary levers for speeding certain programs.